RE: Valuation5 Feb 2019 09:39
Nicely structured argument. Did your NAV take into account the long patent protection, and additional revenues from HAPB. MSSA, MRSA and lung infection treatment in CF patients? I guess that could be upside kicking in at the time of peak sales? I would imagine this applications may well be filed under separate patents. Ad you said its a new drug and hence if approved opens a new chapter in fighting AB resistance